Overview 2NN & CHARM Long-Term Follow-up Study Status: Completed Trial end date: 2007-04-01 Target enrollment: Participant gender: Summary It is desirable to obtain extended follow up data on subjects who participated in the 2NN study and the CHARM study in order to see if the beneficial effect of using nevirapine continues up to 144 weeks of treatment. Phase: Phase 4 Details Lead Sponsor: International Antiviral Therapy Evaluation CenterCollaborator: Boehringer IngelheimTreatments: EfavirenzLamivudineNevirapineStavudine